BEST AVAILABLE COPY

I. Amendments to the Claims

This listing of claims replaces without prejudice all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. (Currently amended) A method of inhibiting a neurotrophin-mediated activity in a mammal comprising the step of administering to said mammal an effective amount of a pharmaceutical composition comprising a compound of Formula I,

$$0 \xrightarrow{\mathbb{R}^1} 0$$

$$0 \xrightarrow{\mathbb{R}^2} \mathbb{R}^2$$

wherein

R¹ is selected from alkyl; aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with a hydroxyloweralkyl; benzimidaz<u>ol</u>-2-yl;

wherein R^4 is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl; NHCH₂CH₂OX wherein X represents an in vivo hydrolyzable ester; and C_2 - C_4 alkyl- $(R^5)(R^6)$ wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy-loweralkyl and loweralkoxycarbonyl; and

R² and R³ are independently selected from H, NO₂, halo, di(loweralkyl)amino, cyano, C(O)OH, phenyl-S-, loweralkyl, and Z(O)OR⁷ wherein Z is selected from C and S and R⁷ is selected from H, loweralkylamino and arylamino, with the provisos that: (i) R² and R³ are not both hydrogen, and (ii) when R³ is NO₂, R¹ is not benzyl;

and or a pharmaceutically acceptable salts salt thereof, in an amount effective to inhibit neurotrophin mediated activity, and

a pharmaceutically acceptable carrier.

2. (Currently amended) A pharmacounical composition The method according to claim 1, wherein R¹ is selected from alkyl; aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with a hydroxyloweralkyl; benzimidaz<u>ol</u>-2-yl;

wherein R^4 is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl; NHCH₂CH₂OX wherein X represents an in vivo hydrolyzable ester; and C_2 - C_4 alkyl- $(R^5)(R^6)$ wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy-loweralkyl and loweralkoxy-carbonyl; and

 R^2 and R^3 are independently selected from H, NO₂, halo, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that R^2 and R^3 are not both hydrogen.

3. (Currently amended) A-pharmaceutical composition The method according to claim 2, wherein R^1 is selected from aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with hydroxyloweralkyl; benzimidazol-2-yl; NHCH₂CH₂OX wherein X represents an in vivo hydrolyzable ester; and C_2 - C_4 alkyl- $(R^5)(R^6)$ wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy-loweralkyl and loweralkoxy-carbonyl; and

 R^2 and R^3 are independently selected from H, NO₂, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that R^2 and R^3 are not both hydrogen.

4. (Currently amended) A pharmacoutical composition The method according to claim 3, wherein R¹ is selected from amino monosubstituted or disubstituted with hydroxyloweralkyl;

NHCH₂CH₂OX wherein X represents an in vivo hydrolyzable ester; and C_2 - C_4 alkyl- $(R^5)(R^6)$ wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy-loweralkyl and loweralkoxy-carbonyl; and

R² and R³ are independently selected from H, loweralkyl and NO₂, with the proviso that R² and R³ are not both hydrogen.

5. (Currently amended) A method of inhibiting a neurotrophin-mediated activity in a mammal comprising the step of administering to said mammal an effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

2-{2-(4-Methylphenylsulphonamido)phenyl}-6-(N,N-dimethylamino)naphthalimide;

N-Octyl-5-nitronaphthalimide;

3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

2-(Benzimidazol-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

3-Methyl-3-(1,3-dioxo-5-nitro(1H,3H)benz[de]isoquinolyl)butyric acid methylester;

N-(4-Ethoxyphenyl)-5-nitronaphthalimide;

Naphthalic_acid-N,N'-diimide;

5-Amino-N-butylnaphthalimide; and

N-(1,3-Dioxo-6-phenylmercapto-1,2,3,4-tetrahydrobenzo[i]isoquinoline)aminoethanol; and or

a pharmaceutically acceptable salts salt thereof, in an amount effective to inhibit

neurotrophin-mediated-activity; and

- a pharmaceutically acceptable carrier.
- 6. (Currently amended) A pharmaceutical composition The method according to claim 5 wherein the compound is selected from the group consisting of:
 - N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;
 - N-Octyl-5-nitronaphthalimide;
 - 3-Amino-7,4-bis(ethyl-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline); and
 - 2-(Benzimidazol-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline.
- 7. (Currently amended) A pharmaceutical composition The method according to claim 1 wherein the compound of Formula I is N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol or its pharmaceutically acceptable salt.
- 8. (Cancelled)
- 9. (Cancelled)
- 10. (Currently amended) A The method for inhibiting a neurotrophin mediated activity comprising the according to claim 1, wherein said step of administering comprises the step of exposing neuron cells to an effective amount of a the pharmaceutical composition as defined in claim 1.

- 11. (Cancelled)
- 12. (Currently amended) A The method as defined in claim 11., wherein said composition is administered intraventricularly.
- 13. (Currently amended) An A method of inhibiting a neurotrophin-mediated activity in a mammal comprising the step of administering to said mammal an effective amount of a pharmaceutical composition comprising an in vivo hydrolyzable ester or amide of a compound selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

- 3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and
- 2-(2-Hydroxyphenyl)naphthalimide; and
- a pharmaceutically acceptable carrier.
- 14. (Cancelled)
- 15. (Cancelled)
- 16. (Cancelled)
- 17. (Cancelled)
- 18. (Cancelled)

- 19. (Cancelled)
- 20. (Currently amended) A method of inhibiting a neurotrophin-mediated activity in a mammal comprising the step of administering to said mammal an effective amount of a pharmaceutical composition comprising N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol or its pharmaceutically acceptable salt, in an-amount effective to inhibit pain, and a pharmaceutically acceptable carrier.
- 21. (Cancelled).
- 22. (Currently amended) A The method for treating pain comprising the according to claim 20, wherein said step of administering comprises the step of exposing neuron cells to an effective amount of a the pharmaceutical composition as defined in claim 20.
- 23. (Cancelled)
- 24. (Currently amended) A The method as defined in claim 2320, wherein said composition is administered intraventricularly.
- 25. (Cancelled)
- 26. (Cancelled)
- 27. (Cancelled)

- 28. (Cancelled)
- 29. (Cancelled)
- 30. (Cancelled)
- 31. (Cancelled)
- 32. (Cancelled)
- 33. (Cancelled)
- 34. (Cancelled)
- 35. (New) The method as defined in claim 1, wherein the neurotrophin-mediated activity is selected from the group consisting of neurotrophin binding to a p75^{NGFR} receptor, neurotrophin binding to a trk receptor, neuron process formation, neurite outgrowth and enzyme induction.
- 36. (New) The method as defined in claim 5, wherein the neurotrophin-mediated activity is selected from the group consisting of neurotrophin binding to a p75^{NGPR} receptor, neurotrophin binding to a trk receptor, neuron process formation, neurite outgrowth and enzyme induction.
- 37. (New) The method as defined in claim 13, wherein the neurotrophin-mediated activity is selected from the group consisting of neurotrophin binding to a p75^{NGFR} receptor,

neurotrophin binding to a trk receptor, neuron process formation, neurite outgrowth and enzyme induction.

38. (New) The method as defined in claim 20, wherein the neurotrophin-mediated activity is selected from the group consisting of neurotrophin binding to a p75^{NGFR} receptor, neurotrophin binding to a trk receptor, neuron process formation, neurite outgrowth and enzyme induction.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.